Illumina, Inc. (ILMN) Shares Bought by Security Asset Management

Security Asset Management grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.9% in the first quarter, Holdings Channel reports. The fund owned 10,837 shares of the life sciences company’s stock after purchasing an additional 92 shares during the period. Illumina accounts for about 2.2% of Security Asset Management’s investment portfolio, making the stock its 13th largest holding. Security Asset Management’s holdings in Illumina were worth $3,367,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Oregon Public Employees Retirement Fund lifted its position in Illumina by 66,581.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after buying an additional 10,546,495 shares during the last quarter. Norges Bank bought a new stake in Illumina in the 4th quarter worth approximately $514,627,000. Jennison Associates LLC lifted its position in Illumina by 13.5% in the 4th quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after buying an additional 653,348 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Illumina by 362.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 433,566 shares of the life sciences company’s stock worth $130,039,000 after buying an additional 339,908 shares during the last quarter. Finally, Vanguard Group Inc lifted its position in Illumina by 1.8% in the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after buying an additional 188,516 shares during the last quarter. Hedge funds and other institutional investors own 90.80% of the company’s stock.

ILMN stock traded down $4.78 during midday trading on Tuesday, hitting $319.98. The company had a trading volume of 3,396 shares, compared to its average volume of 1,087,862. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. Illumina, Inc. has a 52 week low of $250.05 and a 52 week high of $372.61. The company has a market capitalization of $47.85 billion, a P/E ratio of 56.13, a PEG ratio of 2.27 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.34 by $0.26. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The firm had revenue of $846.00 million for the quarter, compared to analysts’ expectations of $838.70 million. During the same period in the previous year, the firm earned $1.45 earnings per share. The business’s revenue was up 8.2% compared to the same quarter last year. As a group, equities analysts predict that Illumina, Inc. will post 6.68 earnings per share for the current year.

In other news, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $321.96, for a total transaction of $1,062,468.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Aimee L. Hoyt sold 298 shares of the business’s stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $304.63, for a total value of $90,779.74. Following the transaction, the senior vice president now directly owns 2,297 shares in the company, valued at $699,735.11. The disclosure for this sale can be found here. Insiders have sold 38,826 shares of company stock worth $12,022,575 over the last three months. Insiders own 0.38% of the company’s stock.

Several analysts have weighed in on the company. Morgan Stanley lowered their price objective on Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research report on Monday, January 7th. Canaccord Genuity reiterated a “buy” rating and issued a $350.00 price objective (down previously from $360.00) on shares of Illumina in a research report on Friday, April 26th. Leerink Swann upgraded Illumina to an “outperform” rating and lowered their price objective for the company from $380.00 to $365.00 in a research report on Wednesday, January 30th. Deutsche Bank downgraded Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective for the company. in a research report on Friday, January 25th. Finally, Bank of America reiterated a “buy” rating and issued a $355.00 price objective on shares of Illumina in a research report on Wednesday, January 30th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $353.58.

COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) Shares Bought by Security Asset Management” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2019/05/07/illumina-inc-ilmn-shares-bought-by-security-asset-management.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Further Reading: What are momentum indicators and what do they show?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.